Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1113.67% is in line with its 1-year average of -1029.37%, around the middle of its 1-year range (-1628.51%–-683.42%).
26.61% below its 12-month average of -879.59%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -828.01%.
EBITDA MARGIN
-1113.67%
EBITDA MARGIN AVG TTM
-879.59%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-26.61%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Aktis Oncology, Inc.
Market Cap
$989.05M
EBITDA Margin
-1113.67%
TTM Avg
-879.59%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$985.79M
EBITDA Margin
-358.45%
TTM Avg
-358.45%
3Y Avg
-358.45%
5Y Avg
-358.45%
Market Cap
$1.03B
EBITDA Margin
13.41%
TTM Avg
11.95%
3Y Avg
15.57%
5Y Avg
17.13%
Market Cap
$943.26M
EBITDA Margin
-64.07%
TTM Avg
-61.50%
3Y Avg
-81.15%
5Y Avg
-81.15%
Market Cap
$1.04B
EBITDA Margin
-351.42%
TTM Avg
-184.18%
3Y Avg
-130.50%
5Y Avg
-161.84%
Market Cap
$1.05B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$922.50M
EBITDA Margin
-189.51%
TTM Avg
-701.94%
3Y Avg
-497.69%
5Y Avg
-575.23%
Market Cap
$921.45M
EBITDA Margin
20.95%
TTM Avg
21.20%
3Y Avg
20.44%
5Y Avg
19.67%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $989.05M | -1113.67% | -879.59% | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | -358.45% | -358.45% | -358.45% | -358.45% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 13.41% | 11.95% | 15.57% | 17.13% |
| CeriBell, Inc. (CBLL)vs › | $943.26M | -64.07% | -61.50% | -81.15% | -81.15% |
| Immatics N.V. (IMTX)vs › | $1.04B | -351.42% | -184.18% | -130.50% | -161.84% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 3.96% | -13.21% | -146.19% | -104.68% |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | -189.51% | -701.94% | -497.69% | -575.23% |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 20.95% | 21.20% | 20.44% | 19.67% |
| Bioventus Inc. (BVS)vs › | $915.95M | 18.58% | 12.56% | -0.37% | 4.16% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | N/A | N/A | N/A |
Gross Margin
100.0%
EBITDA Margin
-1113.7%
Operating Margin
-1149.5%
Net Margin
-727.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -828.01% |
| 2026-03-31 | -683.42% |
| 2025-12-31 | -891.98% |
| 2025-09-30 | -1114.95% |
| 2024-12-31 | -1628.51% |
